Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MURA Stock Forecast 2025-2026
$2.63
Current Price
$45.42M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MURA Price Targets
+128.1%
To High Target of $6.00
+90.1%
To Median Target of $5.00
+52.1%
To Low Target of $4.00
MURA Price Momentum
+3.5%
1 Week Change
+155.3%
1 Month Change
-30.4%
1 Year Change
-18.3%
Year-to-Date Change
-44.5%
From 52W High of $4.74
+176.8%
From 52W Low of $0.95
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Mural Oncology (MURA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MURA and similar high-potential opportunities.
Latest MURA Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, MURA has a neutral consensus with a median price target of $5.00 (ranging from $4.00 to $6.00). Currently trading at $2.63, the median forecast implies a 90.1% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andres Maldonado at HC Wainwright & Co., projecting a 128.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MURA Analyst Ratings
2
Buy
2
Hold
0
Sell
MURA Price Target Range
Low
$4.00
Average
$5.00
High
$6.00
Current: $2.63
Latest MURA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MURA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $6.00 |
| Mar 25, 2025 | Jones Trading | Soumit Roy | Hold | Downgrade | $0.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $18.00 |
| Jan 27, 2025 | Jones Trading | Soumit Roy | Buy | Initiates | $16.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $18.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $18.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Initiates | $18.00 |
| Oct 4, 2024 | Raymond James | Laura Prendergast | Strong Buy | Initiates | $18.00 |
| Jun 28, 2024 | Rodman & Renshaw | Tony Butler | Buy | Initiates | $15.00 |
| Apr 4, 2024 | Morgan Stanley | Judah Frommer | Overweight | Initiates | $13.00 |
Mural Oncology plc (MURA) Competitors
The following stocks are similar to Mural Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MURA
Mural Oncology
mkt cap
45.42M
Mural Oncology plc (MURA) Financial Data
Mural Oncology plc has a market capitalization of $45.42M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -63.6%.
Valuation Metrics
Market Cap
$45.42M
Enterprise Value
$-91,741,728
P/E Ratio
-0.3x
PEG Ratio
-0.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+318.7%
Current Ratio
5.8x
Debt/Equity
5.7x
ROE
-63.6%
ROA
-36.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Mural Oncology plc (MURA) Business Model
About Mural Oncology plc
What They Do
Develops innovative therapies for cancer treatment.
Business Model
Mural Oncology plc generates revenue through the research, development, and commercialization of novel oncology drugs, focusing on precision medicine to tailor treatments based on genetic and molecular profiling. This approach not only improves treatment efficacy but also addresses unmet medical needs in the oncology sector.
Additional Information
The company plays a critical role in advancing cancer research and therapy, contributing to public health improvements and economic activity. Its commitment to personalized healthcare solutions positions it as a significant player in the growing biotechnology industry, with the potential to reduce cancer mortality rates and enhance patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
116
CEO
Ms. Caroline J. Loew Ph.D.
Country
Ireland
IPO Year
2023
Website
www.muraloncology.comMural Oncology plc (MURA) Latest News & Analysis
Latest News
FORM 8.1(a) & (b) - Mural Oncology plc
11 days ago
Quick Summary
Mural Oncology plc has filed an Opening Position Disclosure under the Irish Takeover Panel rules, detailing its interests and short positions.
Why It Matters
The disclosure indicates potential takeover activity involving Mural Oncology plc, signaling possible changes in ownership or control, which can affect stock valuations and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mural Oncology is discontinuing clinical development of nemvaleukin alfa after ARTISTRY trials. With $144.4 million in cash, the company will explore strategic alternatives and reduce its workforce by 90%.
Why It Matters
Mural Oncology's discontinuation of nemvaleukin development and significant workforce reduction signals potential financial instability and strategic shifts, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mural Oncology's stock surged as the company announced it is exploring strategic alternatives to enhance shareholder value following unsuccessful cancer studies for nemvaleukin alfa.
Why It Matters
Mural Oncology's stock surge signals investor optimism about potential asset sales or partnerships, despite setbacks in clinical trials, highlighting volatility and opportunity in biotech investments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Mural Oncology plc (MURA) announced data from the ARTISTRY-7 phase 3 trial, evaluating nemvaleukin alfa combined with Keytruda against single-agent chemotherapy for platinum-resistant ovarian cancer.
Why It Matters
The trial results could impact Mural Oncology's stock price and future partnerships, influencing investor sentiment and market positioning in oncology treatments.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Mural has decided not to advance its trial for platinum-resistant ovarian cancer to final analysis based on interim survival data.
Why It Matters
Mural's decision to halt the trial suggests a potential setback in drug development, which may negatively impact stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The ARTISTRY-7 trial, focusing on platinum-resistant ovarian cancer, will provide an interim overall survival analysis in late Q1 or early Q2 of 2025.
Why It Matters
The upcoming interim analysis in the ARTISTRY-7 trial could impact stock prices of related biotech firms, influencing investment decisions based on potential breakthroughs in ovarian cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MURA Stock
What is Mural Oncology plc's (MURA) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Mural Oncology plc (MURA) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $4.00.
Is MURA stock a good investment in 2025?
According to current analyst ratings, MURA has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MURA stock?
Wall Street analysts predict MURA stock could reach $5.00 in the next 12 months. This represents a 90.1% increase from the current price of $2.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Mural Oncology plc's business model?
Mural Oncology plc generates revenue through the research, development, and commercialization of novel oncology drugs, focusing on precision medicine to tailor treatments based on genetic and molecular profiling. This approach not only improves treatment efficacy but also addresses unmet medical needs in the oncology sector.
What is the highest forecasted price for MURA Mural Oncology plc?
The highest price target for MURA is $6.00 from Andres Maldonado at HC Wainwright & Co., which represents a 128.1% increase from the current price of $2.63.
What is the lowest forecasted price for MURA Mural Oncology plc?
The lowest price target for MURA is $4.00 from at , which represents a 52.1% increase from the current price of $2.63.
What is the overall MURA consensus from analysts for Mural Oncology plc?
The overall analyst consensus for MURA is neutral. Out of 5 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are MURA stock price projections?
Stock price projections, including those for Mural Oncology plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 3:51 PM UTC